Search results for "CD49d"

showing 4 items of 4 documents

Functional Analyses of Human T Cell Extravasation in a Humanized NOD/SCID/IL2Rγcnull Transplantation Model.

2009

Abstract Abstract 2448 Poster Board II-425 Donor lymphocyte graft engineering to avoid graft-versus-host (GVH) reactivity while improving graft-versus-leukemia (GVL) immunity remains of central interest in allogeneic hematopoietic stem cell transplantation (HSCT). However, appropriate models to evaluate experimental concepts of donor lymphocyte allograft engineering in vivo are missing. We, therefore, established a human-murine chimeric transplantation model using immunodeficient NOD/SCID/IL2Rγcnull (NSG) mice to evaluate GVH reactivity of human T cell grafts in vivo. Moreover, since mechanisms of immune functions resembling human GVH immunity have not yet been addressed in detail in these …

Adoptive cell transferCell adhesion moleculeChemistryT cellLymphocyteImmunologyCell BiologyHematologyCD49dBiochemistryTransplantationImmune systemmedicine.anatomical_structureCancer researchmedicineLymphocyte function-associated antigen 1Blood
researchProduct

CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphoc…

2009

AbstractCD38 and CD49d are associated negative prognosticators in chronic lymphocytic leukemia (CLL). Despite evidence that both molecules are involved in interactions occurring between CLL and normal cells in the context of CLL-involved tissues, a functional link is still missing. Using gene expression profiles comparing CD38+CD49d+ versus CD38−CD49d− CLL cells, we showed overexpression of the CCL3 and CCL4 chemokines in cells from the former group. These chemokines were also up-regulated by CD38 signals in CLL; moreover, CCL3 was expressed by CLL cells from bone marrow biopsies (BMB) of CD38+CD49d+ but not CD38−CD49d− cases. High levels of CCR1 and, to a lesser extent, CCR5, the receptors…

Cancer ResearchChemokineChronic lymphocytic leukemiaIntegrin alpha4ApoptosisCD38immune system diseaseshemic and lymphatic diseasesReceptorsChronicMacrophages; Apoptosis; Membrane Glycoproteins; Humans; Integrin alpha4; Antigens CD38; Vascular Cell Adhesion Molecule-1; Endothelial Cells; Receptors Chemokine; Antigens CD31; Cell Survival; Bone Marrow Cells; Leukemia Lymphocytic Chronic B-Cell; Antigens CD; Up-Regulation; Chemokine CCL4; Chemokine CCL3; Cell LineChemokine CCL4Chemokine CCL3Membrane GlycoproteinsLeukemiaCell adhesion moleculehemic and immune systemsLymphocyticCDUp-RegulationPlatelet Endothelial Cell Adhesion Molecule-1Leukemiamedicine.anatomical_structureOncologyChemokineReceptors ChemokineTumor necrosis factor alphaStromal cellCell SurvivalVascular Cell Adhesion Molecule-1Bone Marrow CellsBiologyCell LineAntigens CDmedicineHumansAntigensMonocyteMacrophagesB-CellEndothelial Cellsmedicine.diseaseADP-ribosyl Cyclase 1Leukemia Lymphocytic Chronic B-CellCLL integrins chemokines CD49d CD38 prognosis.Cancer researchbiology.proteinCD31Settore MED/15 - Malattie del SangueCD38
researchProduct

Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaem…

2010

ChemokineChronic lymphocytic leukemiaT-LymphocytesCCL3CD38Settore MED/08 - Anatomia PatologicaCD49dMonocytesMacrophages; Tumor Cells Cultured; Leukemia Lymphocytic Chronic B-Cell; Humans; Monocytes; Chemokine CCL4; Chemokine CCL3; T-LymphocytesTumor Cells CulturedMedicineMacrophageHumansChronicChemokine CCL4Chemokine CCL3CulturedLeukemiabiologybusiness.industryMonocyteMacrophagesB-CellHematologyT lymphocytemedicine.diseaseLeukemia Lymphocytic Chronic B-CellLymphocyticTumor Cellsmedicine.anatomical_structureImmunologybiology.proteinbusinessSettore MED/15 - Malattie del SangueCCL3/CCL4 CD38CD49d chronic lymphocitic leukemia
researchProduct

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab

2015

International audience; Natalizumab (NTZ), a monoclonal antibody recognizing the alpha4 integrin chain, has been approved for the treatment of active multiple sclerosis, but expose to the onset of a rare side effect, progressive multifocal leukoencephalopathy (PML). Estimating the individual risk of PML in NTZ-treated patients is a major challenge, and therapeutic strategies are mainly guided by the overall PML risk assessed by identified risk factors: JC virus (JCV) seropositivity, treatment duration (with peak incidence after 24 months), and the previous use of immunosuppressive therapies. Given that this stratification does not yet allow a precise individual prediction of PML, other pred…

lcsh:Immunologic diseases. Allergy[SDV.IMM] Life Sciences [q-bio]/ImmunologySide effectmedicine.drug_classvirusesImmunologyJC virusReview Articlerisk stratificationCD11aJC virusmultiple sclerosismedicine.disease_causeMonoclonal antibodyCD49dprogressive multifocal leukoencephalopathyNatalizumabeffector memory T-cellst effector memory cellsImmunology and AllergyMedicineselectinPMLbusiness.industryMultiple sclerosisProgressive multifocal leukoencephalopathyvirus diseasesmedicine.disease3. Good healthJCVImmunologySelectins[SDV.IMM]Life Sciences [q-bio]/Immunologylcsh:RC581-607businessmedicine.drugFrontiers in Immunology
researchProduct